• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Director Gandolfo John P

    9/20/24 9:15:49 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $OGEN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    GANDOLFO JOHN P

    (Last) (First) (Middle)
    1990 MAIN STREET, SUITE 750

    (Street)
    SARASOTA FL 34236

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ORAGENICS INC [ OGEN ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    09/19/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Non-Employee Director Option (Right to Buy)(1) $0.48 09/19/2024 A 45,000(1) 09/19/2024(1) 09/19/2034 Common Stock 45,000 $0 45,000(1) D
    Explanation of Responses:
    1. Represents an award of options to purchase shares of the Company's Common Stock under the Company's 2021 Equity Incentive Plan, as amended, pursuant to the Company's non-employee director compensation program. The options vest immediately. The option exercise price is the Company's closing price on the date of grant.
    /s/ Julio C. Esquivel, as Attorney-in-Fact for John Gandolfo 09/20/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $OGEN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OGEN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Odyssey Health, Inc. sold $30,407 worth of Common Stock - OGEN (7,044 units at $4.32), closing all direct ownership in the company (SEC Form 4)

    4 - ORAGENICS INC (0001174940) (Issuer)

    6/18/25 5:10:06 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Odyssey Health, Inc. sold $43,600 worth of Common Stock - OGEN (10,000 units at $4.36), decreasing direct ownership by 59% to 7,044 units (SEC Form 4)

    4 - ORAGENICS INC (0001174940) (Issuer)

    6/16/25 6:01:26 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Odyssey Health, Inc. claimed ownership of 249,623 units of Series F Preferred Stock and claimed ownership of 17,044 shares (SEC Form 3)

    3 - ORAGENICS INC (0001174940) (Issuer)

    6/16/25 5:54:50 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    SEC Filings

    View All

    Oragenics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - ORAGENICS INC (0001174940) (Filer)

    8/11/25 8:30:46 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Oragenics Inc.

    10-Q - ORAGENICS INC (0001174940) (Filer)

    8/8/25 4:16:17 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - ORAGENICS INC (0001174940) (Filer)

    7/2/25 4:30:18 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Goldman Sachs initiated coverage on Oragenics with a new price target

    Goldman Sachs initiated coverage of Oragenics with a rating of Neutral and set a new price target of $52.00

    6/3/21 6:23:39 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oragenics Q2 2025 Shareholder Update

    Advancing Brain-First Recovery Platform Toward Clinical MilestonesPioneering Intranasal Therapeutics for Concussion SARASOTA, Fla., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a pioneering biotechnology company striving to develop brain-targeted therapeutics through proprietary intranasal delivery technology, today shared key strategic and financial milestones achieved during the second quarter of 2025 and shortly thereafter. These successes underscore the company's momentum as it strives to transform neurotrauma care and advance its lead candidate, ONP-002, toward becoming the first FDA-approved pharmacological treatment for concussion. "We're not just developing anot

    8/11/25 8:45:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics Selects Southern Star Research as Clinical Research Organization for ONP-002 Phase IIa Trial

    SARASOTA, Fla., July 31, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a clinical-stage biotechnology company pioneering intranasal drug delivery for neurological conditions, today announced the selection of Southern Star Research as its Clinical Research Organization (CRO) for the upcoming Phase IIa clinical trial of ONP-002, the company's lead drug candidate for concussion. Southern Star Research is a globally recognized, full-service CRO with a proven track record in delivering early-phase trials across Australia and Asia-Pacific. Their deep operational expertise, regulatory knowledge, and hands-on site management capabilities will support the execution of Oragenics' randomized

    7/31/25 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics, Inc. Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

    SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of its lead drug candidate, ONP-002, for the treatment of concussion. This agreement is expected to ensure Good Manufacturing Practice (GMP)-compliant drug product supply ahead of the planned Phase IIb clinical trials which the Company expects to start next year. T

    7/16/25 8:39:31 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 3:59:00 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Oragenics Inc.

    SC 13G - ORAGENICS INC (0001174940) (Subject)

    9/11/24 7:45:36 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Oragenics, Inc. Chief Medical Officer, Dr. James Kelly, Joins the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health

    SARASOTA, Fla., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, proudly announces that its Chief Medical Officer, Dr. James Kelly, has been appointed to the Medical Board of The Leigh Steinberg Foundation for Concussion, Traumatic Brain Injury, and Brain Health. The Leigh Steinberg Foundation is dedicated to advancing brain health by supporting research, raising awareness, and driving actionable solutions for those affected by concussions and traumatic brain injuries (TBI). Dr. Kelly's appointment to the Medical Board reflects his leadership in brain injury resear

    2/24/25 8:30:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oragenics, Inc. Provides Shareholder Update on Strategic Progress and Announces Janet Huffman as Interim CEO

    SARASOTA, Fla., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company advancing innovative treatments for brain-related health conditions, today provided an update on its strategic progress since its last capital raise in September 2024. The Company also announced the appointment of Janet Huffman as its new interim Chief Executive Officer. Strategic Progress Since Capital Raise Following the Company's $4 million capital raise in September 2024, the Company has made significant advancements, including: Formulation and Device Enhancements: The Company has improved the formulation and intranasal delivery device for ONP-002 and in connection therewith

    1/21/25 8:15:00 AM ET
    $MEDS
    $OGEN
    Other Pharmaceuticals
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Oragenics Appoints William "Frank" Peacock MD as Chief Clinical Officer

    SARASOTA, Fla., May 22, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has appointed Dr. William "Frank" Peacock as its Chief Clinical Officer, who will conduct its anticipated Phase II clinical trial for treating concussion in the Emergency Department ("ED"). Oragenics' lead drug candidate, ONP-002, is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (mTBI), commonly known as concussion, in the field and emergency departments. ONP-002 is a new chemical entity (NCE) designed to target the brain through deliver

    5/22/24 8:00:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $OGEN
    Financials

    Live finance-specific insights

    View All

    Oragenics Announces Recent Capital Raise and Warrant Exercises Totaling $21.9 Million and the Redemption of Its Series C Preferred Stock

    TAMPA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”) announced it has raised approximately $20 million from the sale of common stock through a sales agreement with A.G.P./Alliance Global Partners for an “at-the-market” facility. In addition, the Company also received approximately $1.9 million from the exercise of common stock warrants. In turn, Oragenics has given a notice for the redemption of all outstanding shares of the Company’s Series C, Non-Convertible, Preferred Stock (the “Series C Preferred Stock”) to the holder of the Series C Preferred Stock. Commenting on these developments, Alan Joslyn, President and Chief Executive Offic

    2/12/21 8:00:00 AM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care